Weight Management Program for Treatment-Emergent Weight Gain in Olanzapine-Treated Patients With Schizophrenia or Schizoaffective Disorder: A 12-Week Randomized Controlled Clinical Trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The main objective was to assess the efficacy of a weight management program designed for outpatients taking olanzapine for schizophrenia or schizoaffective disorder and to compare these patients with a randomized control group. The effects of the weight management program were also assessed with regard to safety and quality of life. METHOD: Forty-eight patients were enrolled in a 12-week, randomized, multicenter weight management study. Thirty-three patients were randomly allocated to an intervention group in which they received olanzapine within a weight management program. Fifteen patients were allocated to a control group in which they were given olanzapine treatment as usual outpatients. Weight, body mass index (BMI), and measurements of safety and quality of life were evaluated. The study was conducted from January 7, 2003, to September 16, 2003. RESULTS: Thirty-six patients (75%) completed this study. We found significant differences in weight (-3.94 +/- 3.63 kg vs. -1.48 +/- 1.88 kg, p = .006) and BMI (-1.50 +/- 1.34 vs. -0.59 +/- 0.73, p = .007) change from baseline to endpoint between the intervention and control groups, respectively. Significant differences in weight reduction were initially observed at week 8 (p = .040). No significant differences were found with regard to the safety outcomes. When the ratio of low-density lipoproteins to high-density lipoproteins was calculated, change from baseline was greater in the intervention group than the control group (-0.19 vs. -0.04), but the difference was not statistically significant (p = .556). After the completion of the weight management program, there was a trend toward statistical difference in the physical health score changes between the weight management and control groups (1.12 in the intervention group vs. -0.93 in the control group, p = .067). CONCLUSION: The weight management program was effective in terms of weight reduction in patients with schizophrenia or schizoaffective disorder taking olanzapine and was also found to be safe in terms of psychiatric symptoms, vital signs, and laboratory data. In addition, such a weight management program might improve quality of life in patients with schizophrenia or schizoaffective disorder with respect to their physical well-being.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1×
“Schizophrenic patients may exhibit deficits in attention, motivation, and memory, thereby affecting their ability to benefit from a weight management program.(17) However, some reports have indicated relatively high efficacy with regard to weight control in patients with From the last-observation-carried-forward data…”
Background
Cited by
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., Lehman, A., Tenhula, W. N., Calmes, C., Pasillas, R. M., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp115 · Cited by 774
Obesity Among Those with Mental Disorders
Allison, D. B., Newcomer, J. W., Dunn, A. L., Blumenthal, J. A., Fabricatore, A. N., Daumit, G. L., Cope, M. B., Riley, W. T., Vreeland, B., Hibbeln, J. R., et al. (2009) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.11.020 · Cited by 394
Álvarez-Jiménez, M., Hetrick, S. E., González-Blanch, C., Gleeson, J. F., & McGorry, P. D. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042853 · Cited by 317
Metabolic side effects of antipsychotic medication
Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M., Fleischhacker, W. W., Patsch, J. R., & Ebenbichler, C. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01416.x · Cited by 253
Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial
Scheewe, T. W., Backx, F. J. G., Takken, T., Jörg, F., van Strater, A. C. P., Kroes, A. G., Kahn, R. S., & Cahn, W. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12029 · Cited by 246
The metabolic syndrome and schizophrenia
Meyer, J. M., & Stahl, S. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01317.x · Cited by 245
Teasdale, S. B., Ward, P. B., Rosenbaum, S., Samaras, K., & Stubbs, B. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177139 · Cited by 198
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182
Bonfioli, E., Berti, L., Goss, C., Muraro, F., & Burti, L. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-78 · Cited by 154
Bruins, J., Jörg, F., Bruggeman, R., Slooff, C., Corpeleijn, E., & Pijnenborg, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112276 · Cited by 129
Svatkova, A., Mandl, R. C. W., Scheewe, T. W., Cahn, W., Kahn, R. S., & Hulshoff Pol, H. E. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv033 · Cited by 120
Speyer, H., Jakobsen, A. S., Westergaard, C., Nørgaard, H. C. B., Pisinger, C., Krogh, J., Hjorthøj, C., Nordentoft, M., Gluud, C., Correll, C. U., et al. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000502293 · Cited by 116
Effects of Exercise Therapy on Cardiorespiratory Fitness in Patients with Schizophrenia
SCHEEWE, T. W., TAKKEN, T., KAHN, R. S., CAHN, W., & BACKX, F. J. G. (2012) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e318258e120 · Cited by 79
Gates, J., Killackey, E., Phillips, L., & Álvarez-Jiménez, M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00213-8 · Cited by 72
Gross, J., Vancampfort, D., Stubbs, B., Gorczynski, P., & Soundy, A. (2016) · Disability and Rehabilitation · doi:10.3109/09638288.2015.1024343 · Cited by 45
“Attrition bias, associated with participant dropouts, was a risk in seven studies [11,41,42,49,55,57,58].”
BackgroundTemmingh, H., Claassen, A., van Zyl, S., Carrara, H., Dayakalashe, N. M., Myer, L., & Stein, D. J. (2013) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000036 · Cited by 31
Speyer, H., Nørgaard, H. C. B., Hjorthøj, C., Madsen, T. A., Drivsholm, S., Pisinger, C., Gluud, C., Mors, O., Krogh, J., & Nordentoft, M. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0465-2 · Cited by 20
“Several studies have examined the effect of behavioural and pharmacological interventions targeting single cardiovascular risk factors like obesity, smoking, glucoseintolerance, and dyslipidaemia in patients with schizophrenia [16-24].”
Background
Metadata
- Authors
- Kwon, J. S., Choi, J.-S., Bahk, W.-M., Kim, C. Y., Kim, C. H., Shin, Y. C., Park, B.-J., & Oh, C. G.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-04-15
- Volume
- 67
- Issue
- 04
- Pages
- 547-553
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2090786172
- Cited by
- 150
- References
- 2
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.